Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2 (I-SPY 2 TRIAL)

Trial Profile

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2 (I-SPY 2 TRIAL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Durvalumab (Primary) ; Ganetespib (Primary) ; Ganitumab (Primary) ; Ladiratuzumab-Vedotin (Primary) ; MK 2206 (Primary) ; Neratinib (Primary) ; Olaparib (Primary) ; Patritumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trebananib (Primary) ; Veliparib (Primary) ; Carboplatin; Conatumumab; Cyclophosphamide; Doxorubicin; Figitumumab; Metformin; Paclitaxel; Talazoparib; Trastuzumab emtansine
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms I-SPY-2
  • Most Recent Events

    • 06 Sep 2018 According to a Quantum Leap Healthcare Collaborative media release, new randomized, investigational treatment arm ( Olaparib and durvalumab) included in this study.
    • 05 Jun 2018 Results assessing association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results of a biomarker analysis from this study for MK2206, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top